RTM added as distributor NeuraCeq®
Exciting news! Life Molecular Imaging’s NeuraCeq® 300 MBq/ml solution for injection (florbetaben 18F) will soon be available from Radboud Translational Medicine (RTM) in Nijmegen, The Netherlands. We're delighted to announce that the European Medicine Agency has approved the Type IB variation to the NeuraCeq EU dossier, adding RTM to the distribution network.
For more information on NeuraCeq®, including safety information, please visit: https://neuraceq.com/
![RTM added as distributor NeuraCeq®](https://radboudtranslationalmedicine.nl/cdn/c23b15a6-eef5-4843-a143-f51c61ba0b6a/-/resize/555x/-/format/auto/-/quality/smart/neuraceq.png)
Other news
![RTM receives marketing authorisation for Fludeoxyglucose (18F)](https://radboudtranslationalmedicine.nl/cdn/b4cab29f-4a7a-4a09-a1d0-568d3e3446ea/-/smart_resize/250x170/-/format/auto/-/quality/smart/plc04276-hr.jpg)
RTM receives marketing authorisation for Fludeoxyglucose (18F)
We are happy to announce that RTM has received marketing authorization for 18F-FDG of 17 July 2018....
ABX has received marketing authorisation for the radiotracer Radelumin® in Germany
ABX has received marketing authorisation for the radiotracer Radelumin® in Germany! This marks the 8...
![Production of novel diagnostic radionuclides in small medical cyclotrons](https://radboudtranslationalmedicine.nl/cdn/25b47553-0ca5-49e8-a955-014516c0947d/-/smart_resize/250x170/-/format/auto/-/quality/smart/026radboud-ossip.jpg)
Production of novel diagnostic radionuclides in small medical cyclotrons
Employees from RTM and Radboudumc have published a new article: 'Production of novel diagnostic radi...
![First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer](https://radboudtranslationalmedicine.nl/cdn/6bac4557-a1f4-4d63-9b07-9644f2141bfa/-/smart_resize/250x170/-/format/auto/-/quality/smart/telix-nieuwsbericht.jpg)
First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer
The below product is manufactured at RTM First Patient Dosed in Phase II Study of TLX250-CDx in Tri...
Interested in a collaboration?
Contact us to discuss the possibilities.